About

Ben Auspitz has worked in pharmaceuticals and life-science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents.

Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Modis Therapeutics, Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, Indalo Therapeutics, Akrevia Therapeutics,  and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics. Companies he has funded have brought four drugs through regulatory approval.

He currently serves on the Board of Directors of Indalo Therapeutics, Akrevia Therapeutics, Checkmate Pharmaceuticals, and Compass Therapeutics.

Previously, Ben was involved in F-Prime Capital investments in Modis Therapeutics (acquired by Zogenix),  Symbiomix Therapeutics (acquired by Lupin), Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Dimension Therapeutics (acquired by Ultragenyx), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Unum Therapeutics (NASDAQ:UMRX), Precision Biosciences (NASDAQ:DTIL), Orchard Therapeutics (NASDAQ: ORTX), and Ultragenyx (NASDAQ: RARE).

He holds a B.A. from Harvard University.

  • Akrevia Therapeutics is focused on developing highly-potent, targeted and combinable immuno-oncology therapeutics by delivering natural and engineered biologics in the tumor microenvironment. Learn more at www.akrevia.com.

  • Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Learn more at www.aviditybiosciences.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      San Diego, CA

    • Year Invested

      2014

    • Team

  • Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.

     

  • Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Learn more at www.blueprintmedicines.com.

  • Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Learn more at www.checkmatepharma.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Cambridge, MA

    • Year Invested

      2017

    • Team

  • Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide. Learn more at www.coherus.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Redwood City, CA

    • Year Invested

      2014

    • Team

  • Compass is comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets. Learn more at www.compasstherapeutics.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Cambridge, MA

    • Year Invested

      2015

    • Team

  • Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ:RARE).

  • Indalo Therapeutics, a preclinical biotechnology company dedicated to developing therapies for fibrosis, is formed with an experienced team, strong IP, and robust portfolio of drug candidates. Learn more at www.indalotherapeutics.com.

  • LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.

  • Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Oakland, CA

    • Year Invested

      2018

    • Team

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.

  • Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics. Learn more at www.precisionbiosciences.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Durham, NC

    • Year Invested

      2015

    • Team

  • ReGenX Biosciences (NASDAQ: RGNX)  is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform Learn more at www.regenxbio.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Washington, D.C.

    • Year Invested

      2013

    • Team

  • RespiVert was a drug discovery and development company focused on inhaled therapies for severe respiratory disease. RespiVert was acquired by Centocor Ortho Biotech – a division of Johnson & Johnson.

  • Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.

  • Turnstone Biologics is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.  Learn more at www.turnstonebio.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Ottawa, Canada

    • Year Invested

      2016

    • Team

  • Ultragenyx (NASDAQ: RARE) a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. Learn more at www.ultragenyx.com.

  • Unum (NASDAQ:UMRX) has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. Learn more at www.unumrx.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2014

    • Team